Trial Profile

Olaparib Dose Escalating Trial in Patients Treated With Radiotherapy With or Without Daily Dose Cisplatin for Locally Advanced Non-small Cell Lung Carcinoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Olaparib (Primary)
Indications Carcinoma; Non-small cell lung cancer
Focus Adverse reactions; Biomarker
Acronyms olaparib

Most Recent Events

01 Dec 2020 Protocol was amended to increase patient accrual, for enrollment of oligometastatic patients with a good response to induction chemotherapy and radical treatment of the oligometastasis in the (SC) RT arm.
01 Dec 2020 Results published in the Clinical Cancer Research
13 Mar 2020 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com